DISCOVERING THE NEXT

SL C DRUG

Solgate is advancing the SLC15A4::TASL program for autoimmune diseases and the proprietary discovery engine for the broader solute carrier target class

SLC15A4

Differentiated oral program targeting a key autoimmune protein complex.

Solgate is advancing a novel oral small-molecule approach to treating complex autoimmune and inflammatory diseases. Current treatment landscapes are dominated by biologics that target specific immune cell types or pathways, while autoimmune diseases are driven by complex, interconnected immune mechanisms. By disrupting the interaction between SLC15A4 and TASL, a critical component of innate immune signalling, our development candidates are designed to:

  • reduce type I interferon production
  • suppress autoantibody responses
  • reduce pro-inflammatory cytokine production
  • avoid immune cell depletion

By targeting a central disease signalling mechanism rather than limiting to B-cell- or cytokine-specific modalities, this differentiated approach modulates multiple drivers of inflammation simultaneously, with broad therapeutic potential across autoimmune and inflammatory diseases.

→ Explore the lead program

platform

Essential biology. Proven commercial success. Untapped potential.

Solute carriers (SLCs) are a clinically validated drug target class of membrane transporters, with multiple approved medicines demonstrating therapeutic impact and commercial success. Yet, despite the strong genetic rationale and proven track record, most SLCs remain pharmacologically underexplored, offering substantial opportunities for the development of differentiated medicines.

Discovering small molecules that effectively modulate SLCs is challenging due to their complex membrane biology and the limitations of conventional screening approaches. Solgate solves these challenges through an integrated technology platform built around functional, cell-based assays that capture transporter activity in a biologically relevant environment.

→ Read more

company

World-leading SLC science. Proven drug development expertise.

Founded by accomplished scientific co-founders, Solgate brings together a dedicated discovery team and an experienced drug development team. Combining deep expertise in SLC biology, innovative drug discovery, and translational development, we have assembled the scientific and operational capabilities to deliver the next generation of SLC-targeted medicines.

→ Meet Solgate

careers

Building medicines where biology is rich and chemistry is still open.

Join an interdisciplinary team working across SLC biology, chemistry, screening, computation, and translational science to create first-in-class medicines.

→ Explore careers

contact

Connect with Solgate

For scientific, partnering, investor, and general inquiries, contact our team.

→ Contact us

supported by